CIK 0001649094 · Large accelerated filer
Vaxcyte, Inc.
Sign in to watch- Ticker
- PCVX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464233385
- Phone
- 650-837-0111
- Business address
- 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
- Former names
- SutroVax, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,185,988
- in 8 filings, $4.8M under 10b5-1 plans
Net −$5,185,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-23 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −2,938 | $63.22 | $186K | 387,876 |
| 2024-01-23 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −10,023 | $63.95 | $641K | 377,853 |
| 2024-01-23 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −2,039 | $64.78 | $132K | 375,814 |
| 2024-01-23 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,000 | 663 | ||
| 2024-01-23 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,000 | 105,225 | ||
| 2024-01-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise 10b5-1 | +8,000 | $5.35 | $43K | 87,474 |
| 2024-01-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −4,387 | $60.28 | $264K | 83,087 |
| 2024-01-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −3,127 | $61.19 | $191K | 79,960 |
| 2024-01-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −463 | $61.88 | $29K | 79,497 |
| 2024-01-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −23 | $63.35 | $1K | 79,474 |
| 2024-01-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 384,827 | ||
| 2024-01-02 | Lukatch Heath Director | Option exercise 10b5-1 | +13,000 | $16.00 | $208K | 18,625 |
| 2024-01-02 | Lukatch Heath Director | Sale 10b5-1 | −1,101 | $62.85 | $69K | 17,524 |
| 2024-01-02 | Lukatch Heath Director | Sale 10b5-1 | −7,444 | $63.55 | $473K | 10,080 |
| 2024-01-02 | Lukatch Heath Director | Sale 10b5-1 | −4,164 | $64.28 | $268K | 5,916 |
| 2024-01-02 | Lukatch Heath Director | Sale 10b5-1 | −291 | $65.19 | $19K | 5,625 |
| 2024-01-02 | Lukatch Heath Director | Option exercise · Stock Option (right to buy) 10b5-1 | −13,000 | 15,000 | ||
| 2024-01-02 | Eydelman Mikhail SVP, Gen Counsel & Corp Sec | Option exercise 10b5-1 | +1,667 | $21.41 | $36K | 22,377 |
| 2024-01-02 | Eydelman Mikhail SVP, Gen Counsel & Corp Sec | Sale 10b5-1 | −141 | $62.91 | $9K | 22,236 |
| 2024-01-02 | Eydelman Mikhail SVP, Gen Counsel & Corp Sec | Sale 10b5-1 | −598 | $63.59 | $38K | 21,638 |
Page 35 of 39 · 764 trades